Candel Therapeutics, Inc. CADL Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s additional paid-in capital?
- Candel Therapeutics, Inc. (CADL) reported additional paid-in capital of $376.99M in Q1 2026.
- How has Candel Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Candel Therapeutics, Inc.'s additional paid-in capital increased by 45.3% year-over-year, from $259.46M to $376.99M.
- What is the long-term trend for Candel Therapeutics, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Candel Therapeutics, Inc.'s additional paid-in capital has grown at a 69.0% compound annual growth rate (CAGR), from $20.49M to $282.21M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.